So Type 2 diabetes patients with established high risk or ASCVD, heart failure, and/or chronic kidney disease, the hypoglycemic regimen should choose GLP-1 RAs or SGLT-2i. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.